

14 March 2025

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of <i>applicant</i> :		Advanced Medical Solutions Group plc			
Name of scheme:		Block Scheme for: 1. Deferred Share Bonus Scheme 2. Enterprise Management Incentive Scheme 3. Company Share Option Plan 4. Unapproved Executive Share Option Scheme 5. Long Term Incentive Plan 6. Deferred Annual Bonus Scheme			
Period of return:	From:	6 September 2024	To:	5 March 2025	
Balance of unallotted securities under scheme(s) from previous return:		1. 1,739 2. Nil 3. 141,543 4. 309,392 5. 99,970 6. 246,341			
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1. Nil 2. Nil 3. Nil 4. Nil 5. Nil 6. Nil			
<u>Less:</u> Number of <i>securities</i> issued/allotted under scheme(s) during period:		1. Nil 2. Nil 3. 12,000 4. 142,289 5. 86,084 6. 520			
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:		1. 1,739 2. Nil 3. 129,543 4. 167,103 5. 13,886 6. 245,821			

Number and class of securities originally listed and the date of admission:	4,476,264 ordinary shares of 5p each on 6 September 2018
---	--

Name of contact:	Eddie Johnson
Telephone number of contact:	01606 545506

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations	
ICR Healthcare	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Lucy Featherstone	AMS@icrhealthcare.com
Investec Bank PLC (NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRGPUMCWUPAPUW